Inc. (NASDAQ:INCR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On July 10, 2020, Net Element, Inc., a Delaware corporation (the “Company”), entered into the Amendment No. 1 (the “Amendment”) to the binding letter of intent, dated June 12, 2020 (the “LOI”) with Mullen Technologies, Inc., a California corporation.
The LOI provided that the parties agreed to exclusive negotiations of the transactions contemplated in the LOI from June 12, 2020 until 11:59 p.m. Eastern Time on the date 30 days from the date of the LOI.
to the Amendment, the parties agreed to extend such exclusivity period for an additional 30-day period, to expire on August 11, 2020.
The above description of the Amendment is intended as a summary only and is qualified in its entirety by the terms and conditions set forth therein. A copy of the Amendment is attached hereto as Exhibit 10.1 and is incorporated herein by this reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Net Element, Inc. Exhibit
EX-10.1 2 ex_193784.htm EXHIBIT 10.1 ex_193784.htm Exhibit 10.1 AMENDMENT No. 1 TO THE BINDING LETTER OF INTENT EXECUTED ON JUNE 12,…
To view the full exhibit click here
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
